CT327 Psoriasis Study

Registry ID

EUCTR2011-004640-21

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Creabilis Limited

Start date

2012-01-12

Completion date

2012-09-17

Last update

2026-08-16

Conditions

• Psoriasis Vulgaris

Summary

The principal objective of the study is to determine the efficacy of three strengths of CT327 ointment (0.05%, 0.1% and 0.5%) compared to placebo ointment, when applied twice daily to psoriasis vulgaris lesions for up to 8 weeks.

Locations

• , , UK

Related clinical trials

• Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis
• Psoriatic Immune Response to Tildrakizumab
• Correction of Psoriatic T Cell Signatures by Deucravacitinib
• Proactive TDM Versus Standard Use of Biologics in Psoriasis
• Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
• Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris

View on source registry